A recent publication did shown CMV+ individuals to have reduced antigen-specific responsiveness (less IFN-γ secreting CD4+ T-cells and less neutralizing antibodies) to de novo immunization with a tick-borne encephalitis vaccine compared to CMV− individuals4. The gene discussed is CD4; the disease is tick-borne encephalitis.